MacuLogix Appoints William McPhee as New CEO

MIDDLETOWN, PA, December 19, 2016 – MacuLogix^®, Inc., an innovator in the early detection and tracking of age-related macular degeneration, announced that its Board of Directors has appointed William McPhee as Chief Executive Officer of the company, effective today. Mr. McPhee maintains his position as Board Director, which he has held since 2012, and succeeds John Edwards who has stepped down as the company’s CEO and Board Director.

Tracy Saxton, PhD, Investment Director for Roche Venture Fund, the lead investor in MacuLogix said, “Bill McPhee has a proven track record of building businesses and a true passion for vision-related technology. As a long-term investor in MacuLogix, we are excited to support Bill as he builds on the success the company has achieved under the leadership of John Edwards.” Dr. Saxton added, “We are confident that the AdaptDx will preserve vision for millions of people around the world by changing the way eye care professionals detect and monitor age-related macular degeneration.”                                                  

Mr. McPhee has 35 years of experience in strategy and operations consulting, fund raising, transactions, and venture capital, derived from Bain & Company, PepsiCo, Mi3 Venture Partners (an early stage life science fund) and Lucas, McPhee & Co. He has successfully founded and exited two companies and served as CEO of eSight Corporation, where he led the commercialization of electronic eyewear that enables the legally blind to see. Mr. McPhee is a member of Boston Harbor Angels and Mass Medical Angels, and an advisor to The Capital Network.

“I’ve enjoyed a rewarding career of discovering new technologies and bringing them to market. It has been my honor to partner with Greg Jackson, our Chief Scientific Officer and the inventor of the AdaptDx, to develop a novel medical device that is helping reduce unnecessary blindness associated with AMD,” said John Edwards. “Bill has been a big part of our success as a member of the Board, and I know he will continue to drive MacuLogix forward as its new chief executive.”

“It is an honor to be appointed CEO of MacuLogix at this exciting stage in the company’s growth,” said Mr. McPhee. “I have personally experienced the devastating impact of AMD on a family member. Going forward, I will do everything I can to ensure the AdaptDx becomes the standard of care for AMD in order to reduce blindness and maintain the quality of life for those diagnosed with AMD and their family members.”